23 completed, 11 terminated. 34 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 34 | Completed 23, Terminated 11 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
Follow Stage IV Small Lymphocytic Lymphoma: new trials by email Literature Review of Stage IV Small Lymphocytic Lymphoma trials Research Report on Stage IV Small Lymphocytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2009-07-01 | 2013-01-10 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Fludarabine Phosphate, Cyclophosphamide, Rituximab - Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2009-06-01 | 2020-02-25 |
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) Bendamustine Hydrochloride, Alemtuzumab - Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Case Comprehensive Cancer Center | 9 | 2008-11-01 | 2013-08-22 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction vorinostat, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2007-06-01 | 2014-02-24 |
| Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alvocidib, pharmacological study, laboratory biomarker analysis - B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 24 | 2006-09-01 | 2013-07-02 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2006-05-01 | 2013-05-16 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas belinostat, bortezomib, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 55 | 2006-03-01 | 2013-05-03 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia vorinostat, decitabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2006-02-01 | 2014-08-27 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas tanespimycin, bortezomib, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2004-11-01 | 2014-02-24 |
Showing 20 of 34. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (34) · Lymphoma, B-Cell, Marginal Zone (30) · Lymphoma, Follicular (29) · Lymphoma, Mantle-Cell (29) · Lymphoma, Large B-Cell, Diffuse (28) · Burkitt Lymphoma (27) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Lymphoma, Non-Hodgkin (26) · Lymphoma, Large-Cell, Immunoblastic (25) · Waldenstrom Macroglobulinemia (22) · Hodgkin Disease (21) · Lymphoma, T-Cell, Cutaneous (18) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (18) · Lymphoma, Large-Cell, Anaplastic (17) · Mycosis Fungoides (17)
Chronic Disease (34) · Disease Attributes (34) · Hematologic Diseases (34) · Hemic and Lymphatic Diseases (34) · Immune System Diseases (34) · Immunoproliferative Disorders (34) · Leukemia (34) · Leukemia, B-Cell (34) · Leukemia, Lymphoid (34) · Lymphatic Diseases (34) · Lymphoproliferative Disorders (34) · Neoplasms (34) · Neoplasms by Histologic Type (34) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34)
Rituximab (8) · tanespimycin (4) · Bortezomib (3) · Cyclophosphamide (3) · Vorinostat (3) · alvocidib (3) · Gemcitabine (2) · Lenalidomide (2) · Pharmacogenomic Testing (2) · belinostat (2) · fludarabine phosphate (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2'-fluoro-5-ethylarabinosyluracil (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1)
National Cancer Institute (NCI) (27) · Case Comprehensive Cancer Center (2) · Amir Mortazavi (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Northwestern University (1) · University of Chicago (1)
United States (33) · Canada (2)
John Byrd (2) · Patricia LoRusso (2) · Ramesh Ramanathan (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · Antonius Miller (1) · Chandra Belani (1) · Charles Erlichman (1) · Daniel Mulkerin (1) · George Wilding (1) · Jean Grem (1) · John Sarantopoulos (1) · Joseph Flynn (1)
PMID 26853648, PMID 26943915, PMID 27118540, PMID 28270022, PMID 30562587, PMID 31388792, PMID 33492438, PMID 40720747
U01CA076576 (6), U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), U01CA062502 (3), U01CA062505 (3), P30CA016058 (2), U01CA069852 (2), U01CA069912 (2), U01CA132123 (2), N01CM62208 (1), P30CA014520 (1), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1)